Canada markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2600-0.0200 (-1.56%)
At close: 04:00PM EDT
1.3000 +0.04 (+3.17%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.2800
Open1.2600
Bid1.2200 x 200
Ask1.2700 x 200
Day's Range1.2600 - 1.3200
52 Week Range1.0000 - 5.6400
Volume518,706
Avg. Volume1,529,150
Market Cap110.721M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

    SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and continued dosing in the multiple ascending dose (MAD) cohorts of the r

  • GlobeNewswire

    Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

    – Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory an

  • GlobeNewswire

    Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

    – Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publicatio